Toggle Main Menu Toggle Search

Open Access padlockePrints

Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance

Lookup NU author(s): Professor Stephen O'Brien


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Publication metadata

Author(s): Le Coutre P, Giles FJ, Apperley J, Ottmann OG, Gattermann N, O'Brien SG, Kuliczkowski K, Larson RA, Kim DW, Haque A, Gallagher N, Baccarani M, Kantarjian HM

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: Blood: 49th Annual Meeting of the American Society of Hematology

Year of Conference: 2007

Pages: 145A no. 471

ISSN: 0006-4971

Publisher: American Society of Hematology


Library holdings: Search Newcastle University Library for this item

ISBN: 15280020